Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines

Aung Naing, Shalini Dalal, Maen Abdelrahim, Jennifer J. Wheler, Kenneth C. Hess, Siqing Fu, David S. Hong, Filip Janku, Gerald S Falchook, Alyson Ilustre, Fengying Ouyang, Razelle Kurzrock

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Background: Olanzapine is used for treatment of psychiatric conditions but causes substantial weight gain. This study assessed safety, efficacy, and changes in metabolic cytokines associated with olanzapine administration in patients with cachexia due to advanced cancer. Methods: Patients with cancer-related cachexia were treated with olanzapine (doses ranging from 2.5 to 20 mg daily by mouth). Patients also received anti-neoplastic treatments. Serum samples were collected at baseline and after weeks 1, 2, 4, and 8 for analysis of levels of leptin, growth hormone, ghrelin, and interleukin-6 (IL-6). Results: Of the 39 participants, 31 were evaluable for weight change (N = 6 excluded for new ascites; N = 2, incomplete body weight of data). Toxicities related to olanzapine were somnolence (n = 1), pancreatitis (n = 1), extrapyramidal symptoms (n = 1), and nausea/vomiting (n = 1) (all grade 2). The recommended dose of Olanzapine is 20 mg PO daily for cancer patients (same as FDA approved dose for psychiatric conditions). Samples from 29 patients were eligible for analysis of serum cytokine levels. Mean values of leptin, ghrelin, and growth hormone did not change on treatment, though IL-6 levels increased, perhaps due to tumor progression. There was no association between changes in cytokines and weight. The mean change in slope of weight loss before versus after therapy was 0.24 (95 % CI, −0.08, 0.56; p = 0.13) indicating a trend, albeit not reaching statistical significance, toward attenuation of weight loss. Conclusion: Changes in metabolic cytokines and body weight did not correlate. Treatment with olanzapine had only a modest effect in altering the trajectory of weight loss.

Original languageEnglish (US)
Pages (from-to)2649-2654
Number of pages6
JournalSupportive Care in Cancer
Volume23
Issue number9
DOIs
StatePublished - Oct 1 2015

Keywords

  • Cachexia
  • Cancer
  • Weight gain

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines'. Together they form a unique fingerprint.

Cite this